Company
Therapeutic Areas
Our Pipeline
News
Careers
Contact Us
Select Year
2024
2023
2022
2024.05.28
An Interview with CEO Dr. Joan Shen: Starting a CNS Venture in an Economic Downturn
2024.04.30
NeuShen Therapeutics Initiates First-in-Human Trial of NS-136, a Novel Selective M4 Receptor Positive Allosteric Modulator for the Treatment of Schizophrenia
2024.04.18
NeuShen Therapeutics Announces Four Presentations at the 27th ASGCT Annual Meeting
2024.03.11
NeuShen Therapeutics Granted NMPA-CDE IND Approval for Highly Selective KCNQ2/3 Activator
2023.12.27
NeuShen Therapeutics Announces NMPA-CDE Acceptance of IND Application for Highly Selective KCNQ2/3 Activator
2023.10.24
NeuShen Therapeutics-UMass Chan ALS Program to Present Pre-Clinical Data at ESGCT 2023
2023.10.20
NeuShen Therapeutics Hosted Special Event Featuring Top Gene Therapy and Clinical Psychiatry Experts
2023.09.27
NeuShen Therapeutics Announces Poster Presentation of a Novel Selective M4 Receptor Positive Allosteric Modulator for the Treatment of Schizophrenia at Neuroscience 2023
2023.08.03
NeuShen Therapeutics Announces Poster Presentation of Novel KCNQ2/3 Selective Activator NS-041 at ACS FALL 2023
2023.06.25
NeuShen Therapeutics Company Activities During 2023 BIO International Convention Week
About Us
Mission & Culture
Leadership Team
Depression
Schizophrenia
Neurological Disorders
Pipeline
Clinical Trials
Publications
Copyright © 2025 NeuShen Therapeutics, Inc. All rights reserved.
